Kinesin inhibitor, NMS-P715, Purity ≥98%

Cat. No.: X24-08-YM337

Kinesin inhibitor, NMS-P715, Purity ≥98%

Synonym: 1202055-32-0; NMSP715; NMS P715; N-(2,6-Diethylphenyl)-1-methyl-8-[4-[(1-methylpiperidin-4-yl)carbamoyl]-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide

  • CAS Number: 1202055-32-0
  • Compound CID: 44556162
Product Size
5 mg; 10 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
NMS-P715 is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting kinesin. It targets the CK2, MELK, Mps1, and NEK6.
Molecular Weight
676.73
Molecular Formula
C35H39F3N8O3
Targets
CK2: 5.7 μM (IC50); MELK: 6.01 μM (IC50); Mps1: 182 nM (IC50); NEK6: 6.02 μM (IC50)
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Stability
In its lyophilized form, the chemical remains stable for 36 months.
Quality Level
Research grade
Applications
NMS-P715 is a cytoskeletal signaling inhibitor that can be used for its ability to disrupt protein degradation pathways, leading to accumulation of pro-apoptotic factors and induction of cancer cell death.
Storage
Store at -20ºC, and keep desiccated.
Related Products

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.